Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Companies join forces bringing together Bristol Myers Squibb’s (BMS) deep oncology and clinical development expertise and Tubulis’ differentiated and unique approach to Antibody-Drug- Conjugate (ADC) design with the goal of delivering the true therapeutic potential of ADCs
Tubulis to receive upfront payment of $22.75 million and milestone payments potentially totaling over $1 billion plus tiered royalties on net product sales
BMS to obtain access to Tubulis’ proprietary P5 conjugation and Tubutecan platforms to develop versatile and customizable antibody-drug conjugates for cancer treatment
MUNICH, GERMANY, April 20, 2023 – Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).